Prelude Therapeutics (PRLD) Receives a Sell from Barclays

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at $1.27.

According to TipRanks, Lawson is a 3-star analyst with an average return of 2.7% and a 44.49% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Arcus Biosciences, and Syndax Pharmaceuticals.

In addition to Barclays, Prelude Therapeutics also received a Sell from Morgan Stanley’s Jeffrey Hung in a report issued yesterday. However, on the same day, JMP Securities reiterated a Buy rating on Prelude Therapeutics (NASDAQ: PRLD).

Based on Prelude Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $34.74 million. In comparison, last year the company had a GAAP net loss of $30.61 million

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Prelude Therapeutics (PRLD) Company Description:

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.